The Effect of CaV1.2 Inhibitor Nifedipine on Chondrogenic Differentiation of Human Bone Marrow or Menstrual Blood-Derived Mesenchymal Stem Cells and Chondrocytes
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Cartilage is an avascular tissue and sensitive to mechanical trauma and/or age-related degenerative processes leading to the development of osteoarthritis (OA). Therefore, it is important to investigate the mesenchymal cell-based chondrogenic regenerating mechanisms and possible their regulation. The aim of this study was to investigate the role of intracellular calcium (iCa) and its regulation through voltage-operated calcium channels (VOCC) on chondrogenic differentiation of mesenchymal stem/stromal cells derived from human bone marrow (BMMSCs) and menstrual blood (MenSCs) in comparison to OA chondrocytes. The level of iCa was highest in chondrocytes, whereas iCa store capacity was biggest in MenSCs and they proliferated better as compared to other cells. The level of CaV1.2 channels was also highest in OA chondrocytes than in other cells. CaV1.2 antagonist nifedipine slightly suppressed iCa, Cav1.2 and the proliferation of all cells and affected iCa stores, particularly in BMMSCs. The expression of the CaV1.2 gene during 21 days of chondrogenic differentiation was highest in MenSCs, showing the weakest chondrogenic differentiation, which was stimulated by the nifedipine. The best chondrogenic differentiation potential showed BMMSCs ( and expression); however, purposeful iCa and VOCC regulation by blockers can stimulate a chondrogenic response at least in MenSCs.
Huang J, Zeng N, Xu S, Lv Y, Li X, Yang P Cytotechnology. 2025; 77(1):35.
PMID: 39764424 PMC: 11700074. DOI: 10.1007/s10616-024-00702-6.
Wang X, Li X Heliyon. 2023; 9(7):e17989.
PMID: 37501995 PMC: 10368852. DOI: 10.1016/j.heliyon.2023.e17989.